Please select the outcome measures that correspond to the clinical trial below.
Title: Integrating Sex and Gender Considerations Into a Continuing Professional Development Activity on Diabetes and Depression: Protocol for a Non-Randomized Controlled Trial
Brief Summary: People with type 2 diabetes are twice as likely to experience depression as nondiabetic individuals, and depression in turn increases the risk of diabetes. Clinical care for patients for either condition usually fails to consider the impact of sex and gender on tests, diagnosis and treatment, and evidence on these impacts is limited. The investigators aim to assess the impact of a continuing professional education activity (CPD) on diabetes and depression that includes considerations of sex and gender on the clinical behaviours of French-speaking healthcare professionals in Canada.

In a non-randomised controlled trial, the investigators are assessing the impacts of two CPD activities on depression and diabetes, one that includes considerations of sex and gender, and an identical one that omits sex and gender considerations, on French-speaking healthcare professionals' self-reported clinical behaviors regarding sex and gender considerations post-intervention and at 3 months. Data collection will occur in three distinct locations in Canada. Project development, data collection and analysis and dissemination of results will all integrate considerations of sex and gender. The process of creating a CPD activity that integrates considerations of sex and gender could be scaled up to other CPD activities in other clinical subjects and in other minority languages.


Options:
A: Depression and Well-being Improvements After Cognitive-Behavioral Therapy and Well-Being Therapy as Assessed by Changes in Clinical Interview for Depression, Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-Behavioral Therapy and Well-Being Therapy as Assessed by Changes in Symptom Questionnaire ("Anxiety" Subscale), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Autonomy" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-Behavioral Therapy and Well-Being Therapy as Assessed by Changes in Symptom Questionnaire ("Depression" Subscale), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-Behavioral Therapy and Well-Being Therapy as Assessed by Changes in Symptom Questionnaire ("Somatization" Subscale), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-Behavioral Therapy and Well-Being Therapy as Assessed by Changes in Symptom Questionnaire ("Hostility" Subscale), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Environmental Mastery" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Personal Growth" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Positive Relations" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Purpose in Life" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up); Depression and Well-being Improvements After Cognitive-behavioral Therapy and Well-Being Therapy Assessed by Changes in Psychological Well-Being Scales ("Self-acceptance" Dimension), Compared to Clinical Management (Pre-Treatment, Immediately Post-Treatment, 3-, 6-, 12-, 30-month follow-up)
B: Immediate clinical behavioural intention, as measured by CPD-REACTION questionnaire (Immediately following the intervention); Change from immediate clinical behavioural intention at 3 months, as measured by CPD-REACTION questionnaire (3 months after the intervention)
C: Recruitment Feasibility: Percent of Participants Screened Eligible (6 months); Recruitment Feasibility: Percent of Participants Enrolled (6 months); MBCT Feasibility: Percent of Participants Retained (6 months); Mindfulness Based Cognitive Therapy (MBCT) Feasibility: Percent of Participants Adherent to Treatment (6 months); Mindfulness Based Cognitive Therapy (MBCT) Feasibility: Percent of Participants Adherent to Home Practice (6 months); Control Group Feasibility: Percent of Participants Retained (6 months); Control Group Feasibility: Percent of Participants Adherent to Treatment (6 months); Control Group Feasibility: Percent of Participants Adherent to Home Practice (6 months); Videoconferencing Feasibility: Number of Sessions Missed Due to Technical Problems (6 months); Blood Spot Feasibility: Percent of Blood Spot Samples Submitted at Baseline (At Baseline (Month 0)); Blood Spot Feasibility: Percent of Blood Spot Samples Submitted at Post-intervention (At Post Intervention (Month 3)); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Ratings of Intervention Satisfaction (At post intervention (Month 3)); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Percent of Participants Who Plan to Continue Using the Skills (6 months); Mindfulness Based Cognitive Therapy (MBCT) Acceptability: Percent of Participants Who Would Recommend the Program (6 months); Control Group Acceptability: Ratings of Intervention Satisfaction (6 months); Control Group Acceptability: Percent of Participants Who Plan to Continue Using the Skills (6 months); Control Group Acceptability: Percent of Participants Who Would Recommend the Program (6 months); Videoconferencing Acceptability: Ratings of Videoconferencing Satisfaction (6 months); Blood Spot Acceptability: Blood Spot Collection Ease (6 months); Blood Spot Acceptability: Blood Spot Collection Comfort (6 months)
D: Weight loss (6-12 months)

Answer: B